GlassScriptPhysician profile
Emily Magel
NPI 1386094746
$4,088.81
in general payments reported to CMS, 2019-2025
37 companies · $810 in 2025
The $810 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $689 · 2022: $607 · 2023: $825 · 2024: $1,157 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,792.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $957.50 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $729.68 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $328.13 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $261.85 | 2023-2025 | |
| Astellas Pharma US INC | $225.18 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $221.69 | 2023-2025 | |
| Lilly USA, LLC | $216.99 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $190.47 | 2021-2025 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.56 | 2021-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.82 | 2025 | Caplyta |
| Abbott Laboratories | $63.45 | 2024-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.21 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $50.72 | 2021-2023 | |
| Grifols USA, LLC | $45.35 | 2022-2024 | Prolastin-C Liquid |
| E.R. Squibb & Sons, L.L.C. | $42.46 | 2021-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Magel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.